Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 4/20 | 0.43 |
| ▸ | RXRB | P28702 | 4/20 | 0.43 |
| ▸ | RXRG | P48443 | 4/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | MITF | O75030 | 1/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
| ▸ | STAT1 | P42224 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 3/20 | 0.36 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL631613 | 0.93 | RXRA (0.38) | RXRARXRBRXRGS1PR1SMN1; SMN2 | |
| SCHEMBL630567 | 0.92 | NOTUM (0.41) | RXRARXRBRXRGS1PR1SMN1; SMN2 | |
| SCHEMBL630808 | 0.92 | RXRA (0.38) | RXRARXRBRXRGS1PR1SMN1; SMN2 | |
| SCHEMBL630422 | 0.91 | RXRA (0.41) | RXRARXRBRXRGS1PR1SMN1; SMN2 | |
| SCHEMBL630502 | 0.90 | CTSA (0.37) | RXRARXRBRXRGS1PR1SMN1; SMN2 | |
| SCHEMBL631857 | 0.89 | XDH (0.42) | RXRARXRBRXRGS1PR1SMN1; SMN2 | |
| SCHEMBL630550 | 0.89 | RXRA (0.36) | RXRARXRBRXRGS1PR1SMN1; SMN2 | |
| SCHEMBL9440996 | 0.88 | RXRA (0.42) | RXRARXRBRXRGS1PR1SMN1; SMN2 | |
| SCHEMBL4188103 | 0.88 | S1PR1 (0.45) | S1PR1SMN1; SMN2LMNAMITFS1PR4 | |
| SCHEMBL628828 | 0.88 | F2RL3 (0.38) | RXRARXRBRXRGS1PR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115197160-A | Heterocyclic compounds | 武田药品工业株式会社 | 2022-10-18 | — | — | CN | claimed |
| US-20180237404-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-08-23 | — | — | US | claimed |
| EP-3210973-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-08-30 | — | — | EP | claimed |
| CN-115197160-A | Heterocyclic compounds | 武田药品工业株式会社 | 2022-10-18 | — | — | CN | disclosed |
| CN-107108506-B | Heterocyclic compounds | 武田药品工业株式会社 | 2022-06-21 | — | — | CN | disclosed |
| US-20210340114-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-04 | — | — | US | disclosed |
| EP-3848353-A1 | MEDICAMENTS FOR THE TREATMENT OF OPHTHALMIC DISEASES | Takeda Pharmaceutical Company Limited (JP) | 2021-07-14 | — | — | EP | disclosed |
| US-10975043-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-13 | — | — | US | disclosed |
| US-20200157062-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-05-21 | — | — | US | disclosed |
| US-10544111-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-01-28 | — | — | US | disclosed |
| US-20190119225-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-04-25 | — | — | US | disclosed |
| US-20180237404-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-08-23 | — | — | US | disclosed |
| EP-3210973-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-08-30 | — | — | EP | disclosed |
| EP-2419413-B1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | TAKEDA PHARMACEUTICAL (JP) | 2016-11-23 | — | — | EP | disclosed |
| US-8853215-B2 | Derivatives of N-acyl-N′-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-10-07 | — | — | US | disclosed |
| US-20120071489-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| EP-2419413-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2012-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071489-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | RBP4, RBP1, FABP4 | RXRA 23/4885RXRB 53/4885RXRG 77/4885 |
| US-20190119225-A1 | HETEROCYCLIC COMPOUND | RBP4, RBP1, RARA | RXRA 6/4885RXRB 8/4885RXRG 10/4885 |
| US-20210340114-A1 | HETEROCYCLIC COMPOUND | RBP4, RBP1, RARA | RXRA 6/4885RXRB 8/4885RXRG 10/4885 |
| US-20180237404-A1 | HETEROCYCLIC COMPOUND | RBP4, RBP1, RARA | RXRA 6/4885RXRB 8/4885RXRG 10/4885 |
| US-10975043-B2 | Heterocyclic compound | RBP4, RBP1, RARA | RXRA 6/4885RXRB 8/4885RXRG 10/4885 |
| US-10544111-B2 | Heterocyclic compound | RBP4, RBP1, RARA | RXRA 6/4885RXRB 8/4885RXRG 10/4885 |
| US-20200157062-A1 | HETEROCYCLIC COMPOUND | RBP4, RBP1, RARA | RXRA 6/4885RXRB 8/4885RXRG 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.